Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair

Neoplasia (United States)

Volumn 17, Issue 10, 2015, Pages 757-766

  Kausar, Tasneem ^a   Schreiber, Jason S ^a   Karnak, David ^a   Parsels, Leslie A ^a   Parsels, Joshua D ^a   Davis, Mary A ^a   Zhao, Lili ^b   Maybaum, Jonathan ^a   Lawrence, Theodore S ^a   Morgan, Meredith A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE 1; GEMCITABINE; HISTONE H2AX; HISTONE H3; PHOSPHOTRANSFERASE; RAD51 PROTEIN; UNCLASSIFIED DRUG; WEE1 KINASE; CELL CYCLE PROTEIN; DEOXYCYTIDINE; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RADIOSENSITIZING AGENT; WEE1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CELL SURVIVAL; CHEMORADIOTHERAPY; CLONOGENESIS; CONTROLLED STUDY; DRUG SENSITIZATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RECOMBINATION REPAIR; TREATMENT RESPONSE; TUMOR XENOGRAFT; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DNA DAMAGE; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL PROLIFERATION; CHEMORADIOTHERAPY; DEOXYCYTIDINE; DNA DAMAGE; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RADIATION-SENSITIZING AGENTS; RECOMBINATIONAL DNA REPAIR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85017053517     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2015.09.006     Document Type: Article

References (51)

1. Loehrer P.J., Feng Y., Cardenes H., Wagner L., Brell J.M., Cella D., Flynn P., Ramanathan R.K., Crane C.H., Alberts S.R., et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an eastern cooperative oncology group trial. J Clin Oncol 2011, 29:4105-4112.
2. Ben-Josef E., Schipper M., Francis I.R., Hadley S., Ten-Haken R., Lawrence T., Normolle D., Simeone D.M., Sonnenday C., Abrams R., et al. A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2012, 84:1166-1171.
3. Crane C.H., Varadhachary G.R., Yordy J.S., Staerkel G.A., Javle M.M., Safran H., Haque W., Hobbs B.D., Krishnan S., Fleming J.B., et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011, 29:3037-3043.
4. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardiere C., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
5. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., Korn R.L., Desai N., Trieu V., Iglesias J.L., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011, 29:4548-4554.
6. Iacobuzio-Donahue C.A., Fu B., Yachida S., Luo M., Abe H., Henderson C.M., Vilardell F., Wang Z., Keller J.W., Banerjee P., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009, 27:1806-1813.
7. Morgan M.A., Parsels L.A., Maybaum J., Lawrence T.S. Improving the efficacy of chemoradiation with targeted agents. Cancer Discov 2014, 4:280-291.
8. Morgan M.A., Lawrence T.S. Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. Clin Cancer Res 2015, 21:2898-2904. [in press].
9. Do K., Doroshow J.H., Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle 2013, 12:3159-3164.
10. Beck H., Nahse-Kumpf V., Larsen M.S., O'Hanlon K.A., Patzke S., Holmberg C., Mejlvang J., Groth A., Nielsen O., Syljuasen R.G., et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol 2012, 32:4226-4236.
11. Karnak D., Engelke C.G., Parsels L.A., Kausar T., Wei D., Robertson J.R., Marsh K.B., Davis M.A., Zhao L., Maybaum J., et al. Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer. Clin Cancer Res 2014, 20:5085-5096.
12. Krajewska M., Heijink A.M., Bisselink Y.J., Seinstra R.I., Sillje H.H., de Vries E.G., van Vugt M.A. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene 2012, 32:3001-3008.
13. Ashwell S. Checkpoint Kinase and Wee1 Inhibitors as Anticancer Therapeutics. DNA Repair Cancer Ther 2012, 211-234. [Chapter 10].
14. Guertin A.D., Li J., Liu Y., Hurd M.S., Schuller A.G., Long B., Hirsch H.A., Feldman I., Benita Y., Toniatti C., et al. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol Cancer Ther 2013, 12:1442-1452.
15. Bridges K.A., Hirai H., Buser C.A., Brooks C., Liu H., Buchholz T.A., Molkentine J.M., Mason K.A., Meyn R.E. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 2011, 17:5638-5648.
16. Rajeshkumar N.V., De Oliveira E., Ottenhof N., Watters J., Brooks D., Demuth T., Shumway S.D., Mizuarai S., Hirai H., Maitra A., et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011, 17:2799-2806.
17. Ford J.B., Baturin D., Burleson T.M., Van Linden A.A., Kim Y.M., Porter C.C. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Oncotarget 2015, 6:28001-28010.
18. Dominguez-Kelly R., Martin Y., Koundrioukoff S., Tanenbaum M.E., Smits V.A., Medema R.H., Debatisse M., Freire R. Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol 2011, 194:567-579.
19. Kreahling J.M., Gemmer J.Y., Reed D., Letson D., Bui M., Altiok S. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther 2012, 11:174-182.
20. Sarcar B., Kahali S., Prabhu A.H., Shumway S.D., Xu Y., Demuth T., Chinnaiyan P. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther 2011, 10:2405-2414.
21. Mueller S., Hashizume R., Yang X., Kolkowitz I., Olow A.K., Phillips J., Smirnov I., Tom M.W., Prados M.D., James C.D., et al. Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro Oncol 2014, 16:352-360.
22. Caretti V., Hiddingh L., Lagerweij T., Schellen P., Koken P.W., Hulleman E., van Vuurden D.G., Vandertop W.P., Kaspers G.J., Noske D.P., et al. WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. Mol Cancer Ther 2013, 12:141-150.
23. Hirai H., Arai T., Okada M., Nishibata T., Kobayashi M., Sakai N., Imagaki K., Ohtani J., Sakai T., Yoshizumi T., et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010, 9:514-522.
24. Van Linden A.A., Baturin D., Ford J.B., Fosmire S.P., Gardner L., Korch C., Reigan P., Porter C.C. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther 2013, 12:2675-2684.
25. Pokorny J.L., Calligaris D., Gupta S.K., Iyekegbe D.O., Mueller D., Bakken K.K., Carlson B.L., Schroeder M.A., Evans D.L., Lou Z., et al. The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clin Cancer Res 2015, 21:1916-1924.
26. Hirai H., Iwasawa Y., Okada M., Arai T., Nishibata T., Kobayashi M., Kimura T., Kaneko N., Ohtani J., Yamanaka K., et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009, 8:2992-3000.
27. Indovina P., Marcelli E., Di Marzo D., Casini N., Forte I.M., Giorgi F., Alfano L., Pentimalli F., Giordano A. Abrogating G(2)/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Cancer Biol Ther 2014, 15:380-388.
28. Xia F., Taghian D.G., DeFrank J.S., Zeng Z.C., Willers H., Iliakis G., Powell S.N. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci U S A 2001, 98:8644-8649.
29. Morgan M.A., Parsels L.A., Kollar L.E., Normolle D.P., Maybaum J., Lawrence T.S. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008, 14:5142-5149.
30. Lawrence T.S. Ouabain sensitizes tumor cells but not normal cells to radiation. Int J Radiat Oncol Biol Phys 1988, 15:953-958.
31. Fertil B., Dertinger H., Courdi A., Malaise E.P. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 1984, 99:73-84.
32. Morgan M.A., Parsels L.A., Parsels J.D., Lawrence T.S., Maybaum J. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 2006, 5:1983-1988.
33. Huang X., Halicka H.D., Darzynkiewicz Z. Detection of histone H2AX phosphorylation on Ser-139 as an indicator of DNA damage (DNA double-strand breaks). Curr Protoc Cytom 2004, 27. Suppl 30, 1-7 [Chapter 7:Unit 7].
34. Parsels L.A., Morgan M.A., Tanska D.M., Parsels J.D., Palmer B.D., Booth R.J., Denny W.A., Canman C.E., Kraker A.J., Lawrence T.S., et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009, 8:45-54.
35. Willers H., Taghian A.G., Luo C.M., Treszezamsky A., Sgroi D.C., Powell S.N. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res 2009, 7:1304-1309.
36. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
37. Zhao L., Morgan M.A., Parsels L.A., Maybaum J., Lawrence T.S., Normolle D. Bayesian hierarchical changepoint methods in modeling the tumor growth profiles in xenograft experiments. Clin Cancer Res 2011, 17:1057-1064.
38. Parsels L.A., Qian Y., Tanska D.M., Gross M., Zhao L., Hassan M.C., Arumugarajah S., Parsels J.D., Hylander-Gans L., Simeone D.M., et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res 2011, 17:3706-3715.
39. Engelke C.G., Parsels L.A., Qian Y., Zhang Q., Karnak D., Robertson J.R., Tanska D.M., Wei D., Davis M.A., Parsels J.D., et al. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clin Cancer Res 2013, 19:4412-4421.
40. Zhao H., Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001, 21:4129-4139.
41. Holter S., Borgida A., Dodd A., Grant R., Semotiuk K., Hedley D., Dhani N., Narod S., Akbari M., Moore M., et al. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. J Clin Oncol 2015, 33:3124-3129.
42. Karnak D., Parsels L.A., Maybaum J., Lawrence T.S., Morgan M.A. Combined inhibition of Wee1 and PARP1 sensitizes pancreatic cancer cells to radiation. Cancer Res 2012, 72. [Abstract nr 1459].
43. Wei D., Parsels L.A., Karnak D., Davis M.A., Parsels J.D., Marsh A.C., Zhao L., Maybaum J., Lawrence T.S., Sun Y., et al. Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair. Clin Cancer Res 2013, 19:4422-4432.
44. Morgan M.A., Parsels L.A., Zhao L., Parsels J.D., Davis M.A., Hassan M.C., Arumugarajah S., Hylander-Gans L., Morosini D., Simeone D.M., et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010, 70:4972-4981.
45. Krajewska M., Fehrmann R.S., de Vries E.G., van Vugt M.A. Regulators of homologous recombination repair as novel targets for cancer treatment. Front Genet 2015, 6:96.
46. Esashi F., Christ N., Gannon J., Liu Y., Hunt T., Jasin M., West S.C. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 2005, 434:598-604.
47. Martin Y., Dominguez-Kelly R., Freire R. Novel insights into maintaining genomic integrity: Wee1 regulating Mus81/Eme1. Cell Div 2011, 6:21.
48. Aarts M., Bajrami I., Herrera-Abreu M.T., Elliott R., Brough R., Ashworth A., Lord C.J., Turner N.C. Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways. Mol Cancer Ther 2015, 14:865-876.
49. Do K., Wilsker D., Ji J., Zlott J., Freshwater T., Kinders R.J., Collins J., Chen A.P., Doroshow J.H., Kummar S. Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. J Clin Oncol 2015.
50. Mitchell J.B., Choudhuri R., Fabre K., Sowers A.L., Citrin D., Zabludoff S.D., Cook J.A. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010, 16:2076-2084.
51. Rieckmann T., Kriegs M., Nitsch L., Hoffer K., Rohaly G., Kocher S., Petersen C., Dikomey E., Dornreiter I., Dahm-Daphi J. p53 modulates homologous recombination at I-SceI-induced double-strand breaks through cell-cycle regulation. Oncogene 2013, 32:968-975.